Product Name: CUEDC2 Antibody
Species Reactivity: Human, Mouse, Rat
Tested Applications: ELISA, ICC, WB
Applications: CUEDC2 antibody can be used for detection of CUEDC2 by Western blot at 1 – 2 μg/mL. Antibody can also be used for immunocytochemistry starting at 5 μg/mL.
User Note: Optimal dilutions for each application to be determined by the researcher.
Predicted Molecular Weight: Predicted: 32 kDa Observed: 34 kDa
Immunogen: CUEDC2 antibody was raised against a 19 amino acid synthetic peptide from near the carboxy terminus of human CUEDC2.The immunogen is located within the last 50 amino acids of CUEDC2.
Host Species: Rabbit
Purification: CUEDC2 Antibody is affinity chromatography purified via peptide column.
Physical State: Liquid
CAS NO.: 656820-32-5
Product: Reversine
Buffer: CUEDC2 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration: 1 mg/mL
Storage Conditions: CUEDC2 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Clonality: Polyclonal
Conjugate: Unconjugated
Alternate Names: CUEDC2 Antibody: C10orf66, bA18I14.5, C10orf66, HOYS6, CUE domain-containing protein 2
Accession NO.: NP_076945
Protein Ino: 148596996
Official Symbol: CUEDC2
Geneid: 79004
Background: CUEDC2 Antibody: The CUE (coupling of ubiquitin conjugation to endoplasmic reticulum degradation) domain is an evolutionarily conserved, ~40 amino acid monoubiquitin-binding domain that mediates intramolecular monoubiquitylation. CUE domains are present in eukaryotic proteins that are involved in ubiquitination and protein trafficking pathways and may be required for ubiquitination of the proteins in which they are found. CUEDC2 (CUE domain-containing protein 2) was found through a yeast two-hybrid screening as a protein that interacts with the progesterone receptor (PR) and promotes progesterone-induced PR degradation by the ubiquitin-proteasome pathway. CUEDC2 also decreases the sumoylation of PR. CUEDC2 has also been found to interact with IKK-alpha and IKK-beta and decrease the activation of NF-κB by decreasing the activation of IKK.
PubMed ID:http://aac.asm.org/content/37/8/1580.abstract
